Most Read Articles
Audrey Abella, 07 Feb 2020
The combination of the PD-L1* inhibitor atezolizumab and the VEGF** inhibitor bevacizumab generated substantial and consistent benefits in terms of quality of life (QoL) compared with standard-of-care sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, according to the patient-reported outcomes (PROs) from the IMbrave150*** trial presented at ASCO GI 2020.

NAFLD ups risk of coronary artery calcification

08 Feb 2020

The risk of coronary artery calcification (CAC) is elevated among nonobese men with nonalcoholic fatty liver disease (NAFLD), a recent study has found.

The retrospective cross-sectional study included 7,529 participants (median age, 54 years; 59.5 percent male) who had been evaluated for fatty liver status. The outcome of interest was CAC and whether it occurred differentially according to sex and obesity status.

The median body mass index in the study cohort was 24.1 kg/m2. NAFLD occurred significantly more frequently among participants who were obese, as did abdominal obesity and CAC. Hypertension, diabetes, dyslipidaemia, and current smoking and drinking were all also more prevalent among obese participants.

Multivariate logistic regression analysis identified NAFLD as a significant risk factor for the development of CAC in the overall cohort (odds ratio [OR], 1.23, 95 percent confidence interval [CI], 1.06–1.44; p=0.007). Being male (OR, 3.24, 95 percent CI, 2.65–3.97; p<0.001) and obese (OR, 1.27, 95 percent CI, 1.08–1.49; p=0.004) had the same effect.

Disaggregating according to obesity status revealed a significant difference in the influence of NAFLD, which only significantly increased the risk of CAC among nonobese participants (OR, 1.25, 95 percent CI, 1.02–1.54; p=0.034) but not among their obese counterparts (OR, 1.20, 95 percent CI, 0.95–1.52; p=0.122). Being male remained a significant risk factor in both subgroups.

Other pertinent risk factors were increasing age, hypertension, diabetes, current smoking and aspartate aminotransferase levels.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 07 Feb 2020
The combination of the PD-L1* inhibitor atezolizumab and the VEGF** inhibitor bevacizumab generated substantial and consistent benefits in terms of quality of life (QoL) compared with standard-of-care sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, according to the patient-reported outcomes (PROs) from the IMbrave150*** trial presented at ASCO GI 2020.